Nephros (NASDAQ:NEPH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Nephros (NASDAQ:NEPH) to a strong-buy rating in a research note published on Saturday.

A number of other analysts have also recently commented on the stock. Maxim Group upped their price target on shares of Nephros from $4.50 to $6.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Weiss Ratings restated a “hold (c)” rating on shares of Nephros in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $5.50.

Nephros Stock Performance

NASDAQ:NEPH opened at $5.24 on Friday. Nephros has a fifty-two week low of $1.36 and a fifty-two week high of $5.98. The company has a 50 day simple moving average of $4.46 and a two-hundred day simple moving average of $3.50. The company has a market capitalization of $55.54 million, a PE ratio of 43.67 and a beta of 1.32.

Nephros (NASDAQ:NEPH) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.04. Nephros had a net margin of 7.95% and a return on equity of 14.89%. The company had revenue of $4.40 million for the quarter, compared to analyst estimates of $3.60 million.

Institutional Trading of Nephros

An institutional investor recently raised its position in Nephros stock. Geode Capital Management LLC increased its position in shares of Nephros Inc. (NASDAQ:NEPH) by 3.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 93,187 shares of the company’s stock after buying an additional 2,898 shares during the quarter. Geode Capital Management LLC owned about 0.88% of Nephros worth $381,000 at the end of the most recent quarter. Institutional investors own 41.10% of the company’s stock.

About Nephros

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.